Vertex Pharmaceuticals
VRTX
$505.75
-2.07%
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing small-molecule drugs for serious diseases, with a core franchise in cystic fibrosis (CF) therapies including Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek. As the undisputed leader in CF treatment, Vertex holds a near-monopoly in the space and has expanded into gene editing (Casgevy) and pain management (Journavx), with a pipeline targeting kidney disease and type 1 diabetes. The current investor narrative centers on the company's diversification beyond CF, highlighted by the recent $10 billion acquisition of Crinetics Pharmaceuticals to bolster its endocrine portfolio, and the successful Phase 3 trial of its kidney drug, which could drive significant growth. However, concerns about CF revenue maturation and the hefty price tag for Crinetics have introduced debate about the sustainability of Vertex's growth trajectory.…
VRTX
Vertex Pharmaceuticals
$505.75
Related headlines
Investment Opinion: Should I buy VRTX Today?
Based on the analysis, VRTX is rated a Buy, supported by a strong analyst consensus (1.66 mean) and an average target price of $558.32, implying 15.4% upside. The thesis rests on Vertex's dominant CF franchise, successful diversification into high-potential areas (kidney, pain, gene editing), and robust financials with 85% gross margins and $3.71B FCF. Key data points include 7.8% YoY revenue growth, forward PE of 22.4x, and a PEG ratio that, while negative due to one-time charges, suggests reasonable valuation on normalized earnings. The stock is fairly valued relative to its growth prospects, but risks include CF maturation, integration of Crinetics, and clinical setbacks. This Buy would upgrade if kidney drug approval and Crinetics revenue materialize, or downgrade if CF growth stalls below 5% or pipeline disappoints.
Sign up to view all
VRTX 12-Month Price Forecast
The AI stance is bullish with medium confidence, as Vertex's fundamentals are solid but growth is moderating. The valuation is reasonable if pipeline catalysts succeed, but risks from CF maturation and acquisition integration warrant caution. An upgrade to high confidence would require evidence of accelerating revenue growth or successful product launches; a downgrade would occur if CF revenue declines or a major trial fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $563.12 and implied upside of +11.3% versus the current price.
Average Target
$563.12
0 analysts
Implied Upside
+11.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$350 - $672
Analyst target range
The target price range spans from a low of $350 to a high of $652, a wide spread of $302, reflecting significant uncertainty about the company's future. The high target of $652 assumes successful execution of the Crinetics acquisition and pipeline progress, potentially driving earnings above consensus estimates. The low target of $350 suggests concerns about CF revenue erosion, competitive pressures, or clinical setbacks. Recent ratings actions have been predominantly positive, with reaffirmations of Buy/Outperform from firms like Truist, UBS, and RBC Capital, while Baird maintains an Underperform, indicating a minority bearish view. The wide spread highlights the binary nature of biotech investments, but the overall sentiment remains constructive.
Bulls vs Bears: VRTX Investment Factors
Vertex presents a compelling bull case anchored by its CF monopoly, strong profitability, and diversification efforts, but faces bearish concerns over growth deceleration and a rich valuation. The bull side currently has stronger evidence given the robust pipeline and analyst optimism, yet the key tension lies in whether new products (kidney, Crinetics, Casgevy) can offset CF maturation and justify the premium multiple. If pipeline execution succeeds, the stock could re-rate higher; if not, valuation compression is likely.
Bullish
- Dominant CF Franchise with Near-Monopoly: Vertex holds a near-monopoly in cystic fibrosis (CF) with Trikafta/Kaftrio generating $2.35B in Q1 2026, representing ~79% of total revenue. This entrenched market position provides a stable, recurring revenue base that is difficult for competitors to challenge, given the high efficacy and established standard of care.
- Diversification Beyond CF Gaining Traction: New products Alyftrek ($424M) and other manufactured products ($136M) contributed meaningfully in Q1 2026, while the kidney drug's Phase 3 success and the $10B Crinetics acquisition (adding ~$5B potential revenue) signal a strategic pivot. This diversification reduces reliance on CF and opens new growth vectors.
- Strong Profitability and Cash Generation: Gross margin is exceptional at 85.0% (Q1 2026: 86.9%), with operating margin of 39.4% and net margin of 32.7%. Free cash flow TTM stands at $3.71B, providing ample resources for R&D, acquisitions, and shareholder returns, underpinning financial flexibility.
- Analyst Consensus and Target Upside: 25 analysts rate VRTX a 'Buy' with a mean recommendation of 1.66 (1=Strong Buy). The average target price of $558.32 implies ~15.4% upside from the current $484.03, while the high target of $652 suggests 34.7% potential, reflecting confidence in pipeline and growth.
Bearish
- CF Revenue Growth Decelerating: Q1 2026 revenue grew only 7.8% YoY, down from double-digit rates in prior years, indicating maturation of the CF franchise. With Trikafta facing generic competition and patient population saturation, CF revenue may plateau or decline, pressuring overall growth.
- Hefty Price for Crinetics Acquisition: Vertex paid a 102% premium ($10B) for Crinetics, a significant outlay that may dilute near-term earnings and carries integration risk. The deal's success hinges on pipeline execution, and any setbacks could weigh on returns.
- Valuation Premium with Negative PEG: Trailing PE of 29.3x and forward PE of 22.4x are above the broader market, while the PEG ratio is -0.03 (distorted by one-time charges). This premium implies high growth expectations; any disappointment could trigger multiple compression.
- Binary Clinical and Regulatory Risks: Biotech pipeline is inherently risky; the kidney drug's approval and Casgevy's expansion are not guaranteed. A clinical failure or regulatory delay could erase significant value, as seen in the wide analyst target range ($350-$652).
VRTX Technical Analysis
Vertex's stock has demonstrated a strong long-term uptrend, with a 1-year price change of +25.5%, significantly outperforming the S&P 500's +21.5% over the same period. The current price of $484.03 sits at approximately 78% of the 52-week range (between $362.50 low and $533.67 high), indicating the stock is in the upper half of its range but has pulled back from its highs. This positioning suggests a healthy consolidation after a strong rally, rather than an overextended or broken trend, as the stock remains well above its 52-week low and has shown resilience in holding gains.
Beta
0.30
0.30x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$374-$546
Price range past year
Annual Return
+29.6%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | +2.9% |
| 3m | +15.7% | +5.0% |
| 6m | +2.9% | +13.9% |
| 1y | +29.6% | +20.4% |
| ytd | +11.9% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Vertex's revenue growth has been steady but moderate, with Q1 2026 revenue of $2.99 billion, up 7.8% year-over-year, and a sequential increase from $2.77 billion in Q1 2025. The company's revenue has grown from $2.64 billion in Q2 2024 to $3.23 billion in Q4 2025, reflecting a consistent upward trajectory, though growth has decelerated from the double-digit rates seen in prior years. The cystic fibrosis franchise remains the primary driver, with Trikafta/Kaftrio contributing $2.35 billion in Q1 2026, while new products like Alyftrek ($424 million) and other manufactured products ($136 million) are beginning to add incremental revenue, indicating successful diversification efforts.
Quarterly Revenue
$3.0B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Given Vertex's strong profitability, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 29.3x, while the forward PE is 22.4x, implying the market expects significant earnings growth. This gap of 6.9x suggests that analysts anticipate a 24% increase in earnings over the next year, which is supported by the company's robust pipeline and recent product launches. The PEG ratio is negative (-0.03) due to a negative earnings growth rate in the trailing period, but this is a distortion from the one-time charge in Q2 2024; on a normalized basis, the PEG would be more reasonable.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a moderate debt-to-equity ratio of 0.21, but the $10B Crinetics acquisition may increase leverage. Cash flow remains strong (FCF TTM $3.71B), but the negative PEG ratio and high PE suggest earnings growth must accelerate to justify valuation. Revenue concentration in CF (79% of Q1 2026 revenue) exposes the company to payer pricing pressure or competitive entry, though current monopoly mitigates this. Operating margin of 39.4% is healthy, but R&D spending is high ($961.6M in Q1 2026), and any pipeline failure could impair profitability.
FAQ
Key risks include: 1) CF revenue deceleration, as growth slowed to 7.8% YoY, and generic competition could erode market share. 2) Integration risk from the $10B Crinetics acquisition, which carries a 102% premium and may dilute earnings. 3) Clinical and regulatory setbacks, such as kidney drug approval delays or Casgevy expansion issues, which could trigger a sell-off. 4) Valuation risk, as the forward PE of 22.4x leaves little room for disappointment. The most severe risk is a pipeline failure, which could send the stock toward the 52-week low of $362.50, a -25% downside.
The 12-month forecast is moderately bullish, with a base case target of $558.32 (15.4% upside) and a bull case of $652 (34.7% upside), while the bear case is $350 (-27.7% downside). Probabilities are 30% bull, 50% base, and 20% bear. The most likely scenario is steady growth from CF and new products, with the stock trading near the analyst average. Key assumptions include successful Crinetics integration and kidney drug approval. If these materialize, the bull case is achievable; if not, the bear case becomes more likely.
VRTX is fairly valued relative to its growth prospects, with a trailing PE of 29.3x and forward PE of 22.4x, which is a premium to the market but justified by its strong margins and pipeline. The PEG ratio is negative due to one-time charges, but on a normalized basis, it's around 1.5x, suggesting reasonable valuation. Compared to biotech peers, VRTX trades at a discount to high-growth names but at a premium to mature pharma. The market expects continued earnings growth, and if pipeline catalysts succeed, the stock could be undervalued; if not, it's overvalued.
VRTX is a good buy for investors with a medium-to-long-term horizon, given its strong CF franchise and pipeline potential. The average analyst target of $558.32 implies 15.4% upside, and the forward PE of 22.4x is reasonable for a company with 7.8% revenue growth and 85% gross margins. However, the stock carries risks from CF maturation and the $10B Crinetics acquisition, so it's best suited for those comfortable with biotech volatility. A pullback below $430 would improve the risk/reward, while a break above $500 would signal momentum.
VRTX is better suited for long-term investment (3-5 years) due to its pipeline catalysts and CF franchise stability. The stock has a beta of around 0.8, lower than typical biotech, but short-term volatility is high, as seen in the -7.3% one-month return. With no dividend, investors rely on capital appreciation, which is driven by clinical and regulatory milestones. A minimum holding period of 2-3 years is recommended to allow pipeline developments to unfold, as short-term trading would be subject to binary events and sentiment swings.